Market Place
Sourcing Support
FDA Grants Priority Review For Neurocrine`s Crinecerfont In CAH
01 Jul 2024 //
PR NEWSWIRE
Neurocrine Receives Breakthrough Therapy Designation from FDA for Crinecerfont
05 Dec 2023 //
PR NEWSWIRE
Neurocrine Biosciences Announces Phase 3 Pediatric Study Results of Crinecerfont
05 Oct 2023 //
PR NEWSWIRE
Neurocrine`s crinecerfont succeeds in congenital adrenal hyperplasia trial
13 Sep 2023 //
PR NEWSWIRE
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.